COMMERCIAL/MEDICAL STRATEGY Mulrooney

PERSONAL PROFILE

  • 24 years in pharma medical management/leadership and commercialization strategies.

EXPERTISE

Global Medical Leadership, Strategy and Operations, Commercial Assessment, In-Licensing, R&D, Medical Affairs, Marketing and Sales, Business Development, Change Management, Physician, Specialties: Small Molecules/Biopharmaceuticals, Hospital Internal Medicine, Cardiology, Immunology/Inflammation, Ophthalmology, Cardiovascular Diseases, Diabetes Mellitus, Osteoporosis, Stress Urinary Incontinence, and Rare Diseases (Pulmonary Arterial Hypertension and System Lupus Erythematosus/SLE).

MB, BCh, BAO from University College Cork Medical School, National University of Ireland.

Founder/Managing Director, Ardiem Lifesciences Ltd.
Biotech consultant providing strategic commercial support. Producing long- and short-range strategic plan for mid-size rare disease biotech leader. Executing launch of a rare disease web-based application. Delivered strategic assessment of a spin-out option of a Phase II asset at a mid-size Japanese company. Produced an indication prioritization report for a VC-backed start-up in inflammation and ophthalmology as well as positioning recommendation and implications for development plan at a start-up with a suite of ophthalmology assets.

Vice President, Medicine Commercialization Leader, GlaxoSmithKline Pharmaceuticals
As “CEO” of Benlysta (belimumab), an infusible biopharmaceutical approved globally and launched in 2011 as the first new medicine in over 50 years for the treatment of the auto-immune disorder SLE (‘Lupus’), accountable for vision, strategy, and delivery of global tactical program. Current value ~ £200million with YoY growth >25% in 2014. Managed a variable spend budget of £6-8million and worldwide oversight of Commercial, Market Access, Medical Affairs, and Life-cycle Strategy: delivered first-ever global strategy, first-ever suite of global campaign and tactics, and first-ever IP global strategy for product. Co-chaired Medicine Development Team.

Vice President, Commercial Center of Excellence, Head of Cardiovascular, Metabolic, and Musculoskeletal Diseases, GlaxoSmithKline Pharmaceuticals
Led and managed multi-functional department comprising Marketing, Commercial Analytics, Market Access, and Medical Affairs. Accountable for above-country P&L for Prolia in osteoporosis and Xgeva in metastatic breast and prostate cancer as well as commercial strategy, marketing, market access, and medical affairs tactical support for Avandia (rosiglitazone, an orally-administered medicine for the treatment of Type II Diabetes Mellitus), Prolia for osteoporosis, and Xgeva. Successfully launched Prolia (denosumab) as a co-promotion of GSK and Amgen EU and US as well as commercial launches of denosumab (‘Xgeva’) as a GSK-only venture in non-US, non-EU markets. As key leader, set up and led the first-ever ex-US systematic, wide sweep of cardiovascular, metabolic, and musculoskeletal business development activities resulting in Amgen partnership; accountable for overall success of collaboration. Led strategy and market support (ex-US) of Avandia through a period of intense media and regulatory scrutiny of its safety record. Accountable for commercial leadership on broad range of cardiovascular, metabolic, musculoskeletal, and ophthalmology early- and late- stage assets. Responsible for developing ex-US medicine vision, commercial, market access, and medical affairs strategies leading to evidence plan and development strategy for early stage assets including: Albiglutide a Glucagon-like Peptide agonist now approved as Tanzeum/Eperzan for subcutaneous injection in the treatment of Type II Diabetes Mellitus; Darapladib during Phase II/III development for cardiovascular disease; Losmapimod, currently in Phase III development for treatment of Acute Coronary Syndromes; Prolyl Hydroxylase Inhibitor for treatment of renal anaemia; and all GSK ophthalmology pipeline and business development activity (including two Due Diligence exercises). Other business development interactions and due diligence activities include novel methods of delivering the effects of bariatric surgery without surgery, innovative insulin pumps and blood glucose monitoring, mobile phone technologies to deliver better diabetes care, and front and back of eye ophthalmology